Compare Inovio Pharmaceuticals Inc (INO) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while SiTime Corporation trades at $585.89 (market cap $16.63B). The key difference: SiTime Corporation is far larger — about 186.3× Inovio Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SITM | |
|---|---|---|
Market Cap | $89.27M | $16.63B |
Sector | Health | Technology |
52-Week High | $2.87 | $901.60 |
52-Week Low | $1.05 | $190.16 |
Enterprise Value | $60.28M | $15.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
SITM trades at $555.15, showing minimal daily movement with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth and completed the acquisition of Renesas' timing business, but faces negative net income margins and high valuation multiples. Analyst consensus remains strongly bullish with a $825 price target, highlighting growth potential from AI infrastructure demand.
The outlook is mixed: robust revenue growth and strategic acquisitions support long-term potential, but profitability challenges and bearish technical indicators present near-term risks. Investors should weigh strong analyst confidence against execution risks and current negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
